Exicure (XCUR) Restructuring Costs (2023 - 2024)
Exicure (XCUR) reported Restructuring Costs of $424000.0 for Q4 2024, down 54.8% on a YoY basis from $938000.0 in Q1 2024, and down 62.74% quarter-over-quarter from $1.1 million in Q3 2024.
Exicure (XCUR) Restructuring Costs (2023 - 2024) Analysis & Trends
Exicure has reported Restructuring Costs for 2 years, with the latest figure at $424000.0 in Q4 2024.
- For the quarter ending Q4 2024, Restructuring Costs fell 54.8% year-over-year to $424000.0; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (down 37.52% YoY), and the FY2024 full-year result was $1.6 million, up 66.52% from the prior year.
- Restructuring Costs for Q4 2024 stood at $424000.0, down from $1.1 million in the prior quarter.
- The five-year high for Restructuring Costs was $1.1 million in Q3 2024, with the low at $424000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 424,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Dec 31, 2023 | 938,000.00 |